Board of Directors

The Inventor

Professor-Yechezkel-Barenholz

Prof. Yechezkel Barenholz

(PhD)

World class key opinion leader in Liposomes & one of the key inventors of DOXIL (the first Liposomal drug), marketed by Johnson & Johnson as a cancer treatment.

  • Professor Emeritus Yechezkel (Chezy) . Barenholz is a highly accomplished entrepreneur and internationally recognized expert in the fields of biochemistry, biophysics and liposomes-based drug development. Startups based on Prof. Barenholz’ inventions and know how, include 6 start-ups: PolyPid LTD;  NasVax Ltd (Now Theapix LTD); Moebious Medical LTD; LipocureRX LTD; Ayana Pharma LTD; Re-BioticRX LTD.
  • Professor Emeritus Yechezkel (Chezy) Barenholz is head of the Liposome and Membrane Research Lab at the Hebrew University-Hadassah Medical School, Jerusalem, Israel and is also the Daniel G. Miller Professor in Cancer Research at Hebrew University of Jerusalem. He has been on the faculty at Hebrew University since 1968 and has been a visiting Professor at leading Universities around the world.
  • Author of over 420 scientific publications , cited >35,500 times, with h-index 93.
  • Inventor of >55 approved patent families (>50% licensed).
  • Barenholz current research focuses on the development of drugs and nano-drugs based liposomes. This is best exemplified by the anticancer  Doxil®, the first liposomal drug as well as the first nano-drug approved by the FDA (1995) which is based on Barenholz I.P. and delomental work. So-far over 700,000 cancer-patients globaly were treated with Doxil.
  • Prof Barenholz received many National and International awards including Honorary Doctorate degree from the Technical University of Denmark (2012) and the 2012 founders award of the International Controlled Release Society
Dr. Liana Patt

Dr. Liana Patt

(PhD, MBA)

Dr. Patt currently serves as CEO of Integra Holdings, the VC arm of the Hebrew University Life Sciences IP.
Dr. Patt’s experience includes VP Business Development, Global Branded Products at Teva Pharmaceutical Industries.
Dr. Patt managed a global team (US, Europe, Israel) and was responsible for evaluating hundreds of business opportunities in diverse therapeutic fields and various development stages, technologically, medically and commercially.

Liora-Ettinger

Liora Ettinger

(MBA)

Liora Ettinger currently serves as CEO of Ilan Holdings, a private investment fund, focused on Israeli disruptive new technologies.
Liora joined Ilan Holdings in 2014 as CFO and member of the Executive Committee, and has served as the company’s CEO since 2016. Since 2003 Liora has been involved in financial management in global leading companies, including Africa Israel Investments (TASE:AFIL), Redstone Real Estate Investments, Giza Singer Even and Mizrahi Bank.

error: Content is protected !!